At GenPro, We’ve Opened the Door to a New Class of Dynamic, Blood-Based, Immune System Epigenetic Biomarkers Called “EpiMarkers”.
We are an immune system focused functional epigenomics company that is creating a new category of molecular diagnostic and drug response stratification blood tests to solve unmet clinical needs across the oncology and non-onclogy disease spectrum that other techniques cannot easily or economically address, all from a standard, non-invasive blood draw.
Unique to GenPro is its cloud-based EpiMarker Platform which combines novel, proprietary science and machine learning to rapidly discover and elucidate the immune system’s circulating white blood cells’ genome-wide epigenetic (DNA methylation) response to disease intrusion and drug-induced change into EpiMarkers for translation into blood tests that are easy to perform on standard clinical lab equipment.
A precision EpiMarker blood test to diagnose Endometriosis is the first in a pipeline of new tests being developed. Endometriosis is a painful, progressive pelvic disease affecting ~15% of women between 13-to-40 years of age for which expensive and invasive laparoscopic surgeries are the standard of care for disease diagnosis with erratic accuracy in the 50% to 80% range dependent on the surgeon’s experience and expertise. A precision endometriosis diagnostic blood test with predictive accuracy >85% would change clinical practice, significantly improve patient care, and profoundly reduce the cost of endometriosis care.
GenPro forms cooperative development and licensing partnerships with biopharma, molecular diagnostic, and genomic testing companies wherein GenPro rapidly discovers and develops immuno-EpiMarkers into commercializable tests within 18-24 months for licensing to the partner for commercialization. Cooperative development and licensing partnerships are tailored to each partner’s goals.
From our novel immune system EpiMarkers, to our unique, proprietary machine-learning, cloud-based platform, to our pipeline of EpiMarker blood tests, to our cooperative partnership methodology, GenPro is providing a proven architecture for success.
The GenPro Platform - Improving Results Across Health Care by Decoding the Immune System's Epigenome.
Uniquely distinguishing Genome Profiling is its proprietary, cloud-based, machine-learning, methyl sensitive restrictive enzyme (MSRE) chemistry and bioinformatics platform called the EpiMarker Platform. Combined with a disciplined workflow, the EpiMarker Platform rapidly (< 10 weeks) discovers and validates each unique immuno-epigenetic response to a disease or disease change and codifies it into a novel computational tool called an EpiMarker. Think of each EpiMarker as a powerful “in silico epigenetic biomarker” that can predict disease or disease change due to therapeutic intervention.
Once an EpiMarker is discovered and validated from a simple blood sample using whole-genome next generation sequencing (NGS), each EpiMarker is translated into a low-cost, high-throughput clinical test that runs on standard clinical lab equipment to provide new clinically actionable information to solve some of the most difficult disease diagnosis and treatment problems that gene mutation biopsy and liquid biopsy biomarkers cannot easily address.
Our Commitment to
Endometriosis is a relatively common, complex, chronic, progressive and intensely painful gynecological condition affecting 10-15% (>70 million) of women between ages 13 – 40 worldwide for which a simple, blood-based precision diagnostic test would significantly improve patient care and its cost to the health system.
- Improving Clinical Trial Outcomes for New Endometriosis Drugs Using Immune System Derived Epigenetic Biomarkers (EpiMarkers)
- Early Endometriosis Liquid Biopsy Diagnosis with Immune System Derived Epigenetic Biomarker
- Dan C. Martin, MD, Renowned Endometriosis Expert, Joins Genome Profiling’s Clinical and Scientific Advisory Board
A Rich, Dynamic Information Source for Decoding Patterns of Health Status and Therapeutic Response.
About / Team
We are assembling a world-class team that is dedicated to bettering the lives of patients by improving the capabilities of our customers and partners.
Genome Profiling is a functional genomics company focused on decoding the sentinel power of the immune system’s global epigenetic response to acute and chronic health conditions and therapeutic intervention into a pipeline of novel clinical products that deliver transformational benefits to biopharmas, clinicians, patients and payers.
Sharing the benefits of our discoveries with the scientific community through partnerships tailored to your specific goals.
At GenPro, we’ve successfully applied our scalable platform and efficient workflow to enable Biopharma and Research Collaboration Partnerships. Read more about our tailored, staged and milestone driven clinical trial collaboration partnership model.